An interventional study of Cytisine and Nicotine replacement therapy (NRT) in Tobacco Dependence, COPD Asthma and Mental Illness, sponsored by Ottawa Hospital Research Institute. Enrolling by invitation at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Ottawa Hospital Research Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Tobacco Use Disorder with a site in Canada — 10 open to participants now, 10 under way, 1 of them phase 3. Tobacco Use Disorder · Canada.
Among the 43 studies in Tobacco Use Disorder with a site in Canada, this one is the 11th largest by planned enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2025, is one of 19 with no phase, and was the 30th registered.
1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.
Browse Tobacco Use Disorder studies →10 of the 43 studies in Tobacco Use Disorder with a site in Canada are open now. Recruiting first, the newest first:
St. Justine's Hospital · Sites in Canada
Ages 18+
Waypoint Centre for Mental Health Care · Sites in Canada
Ages 18+
Ottawa Heart Institute Research Corporation · Sites in Canada
Ages 18+
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–85
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–70
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 3 · Phase 4 9
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 90 across 893 interventional studies indexed under Tobacco Use Disorder.
Median enrollment 43 across the 41 interventional studies, 180 across the 2 observational. Of the 28 that completed or were terminated, 7 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 43 has an industry lead sponsor. The 10 most frequent:
Ottawa Hospital Research Institute is the lead sponsor of 547 studies on the registry; 99 are open to participants now.
Ottawa Hospital Research Institute has 3 studies filed under Tobacco Use Disorder — fewer than ten, so there is no comparison to draw.
5 of the studies in Tobacco Use Disorder with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059377Phase 3Ottawa Heart Institute Research CorporationSemaglutide for Smoking Cessation in Patients With Diabetes | 2026-12 |
| NCT03249428Ottawa Hospital Research InstituteCytisine vs Nicotine Replacement Therapy | 2027-03 |
| NCT03506867Ottawa Hospital Research InstituteHealthy People Initiative (HPI) | 2027-03-31 |
| NCT06346028Centre for Addiction and Mental HealthImplementation of Transcranial Magnetic Stimulation for Smoking Cessation | 2027-06-30 |
| NCT04163081Ottawa Heart Institute Research CorporationThe INITIATE Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 43 studies in Tobacco Use Disorder with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tobacco is the most preventable cause of disease and death in Canada. Although the tobacco use rate has substantially gone down in the general population, significant differences exist between sub-populations in Canada, for example Ottawa's highly vulnerable homeless or at-risk for homelessness population has an almost 100% tobacco smoking rate relative to 9-18% in the rest of the Canadian general population. This stark inequity in tobacco use translates into devastating healthcare outcomes such as a disproportionate amount of cancer, stroke, heart disease and death. Canadians who are homeless or at-risk for homelessness die 25 years earlier than housed Canadians, mostly due to tobacco. In order to tackle this tobacco use related inequity - a novel approach is urgently needed. Despite commonly held dogma that People Who Use Drugs (PWUD) don't want to quit smoking, many studies have demonstrated that in fact they are very interested in quitting. Moreover, the investigators pragmatic peer-led community-based action approach used in their PROMPT project has demonstrated that tobacco dependence strategies can be implemented with great success in this population. The majority of PROMPT participants reduced or quit tobacco use, in addition to reducing or quitting all other drug use. Importantly, the investigators have demonstrated that it is possible to gain the trust and engagement of marginalized populations and that researchers can create a community space that is low-threshold, safe and non-judgmental. The investigators aim to compare two tobacco dependence management strategies in the homeless (or at-risk for homelessness) multi-drug use population in Ottawa and Toronto. They will use the same peer-led approach in PROMPT with community peer researchers with lived experience; with the hope that the cost-effective community based framework derived from this trial will serve as a template for interventions and treatments in community settings for chronic diseases such as obesity and diabetes.
Aim: A 3-yr multi-centre, pragmatic Randomized Controlled Trial (RCT) to compare effectiveness of Cytisine (with counseling) with peer-led PROMPT strategy (nicotine replacement therapy (NRT) and counseling) for tobacco dependence in the inner-city population.
Background: Homelessness/at-risk for homelessness populations in Canada carry disproportionate burden of many diseases, mostly due to tobacco. With smoking rates at \~100% in some subpopulations as compared to 9-18% in the general population, tobacco inequity is translated into unequal morbidity and mortality (COPD, cancers, heart diseases). Tobacco use costs the Ontario economy \~$1.6 billion/year in healthcare costs. Smoking attributable hospitalization costs \~$38.2 million/year in Ottawa alone from 2008-10. The inner-city population in Canada dies \~25 years earlier than housed Canadians, largely due to tobacco. With negligible quit rates using conventional strategies, novel approaches to address tobacco inequity are urgently needed.
Cytisine is a naturally occurring alkaloid that has long been used as a tobacco dependence treatment and management aid in Eastern Europe. Health Canada has approved Cytisine as an over-the-counter health product, and the Canadian Agency for Drugs and Technologies in Health (CADTH) has determined Cytisine to be a cost-effective tobacco dependence treatment and management aid. Given its cost-effectiveness and affordability compared to nicotine replacement therapy, Cytisine may be more accessible and effective for marginalized populations. Cytisine will be made available to study participants as a Health Canada licensed natural health product.
Study Population: 200 Toronto and Ottawa inner city homeless/at-risk for homelessness participants using poly-substances.
Primary Patient-Oriented Outcome: To assess the impact of two pragmatic tobacco dependence strategies on changes in QOL and GAINSS score measured with the EQ-5D-5L; Secondary: i) To assess effectiveness of these two strategies with biochemically validated smoking abstinence at 13 and 26 weeks; ii) To assess effectiveness of these two strategies on conventional cigarette and/or e-cigarette consumption reduction and cessation at 13 and 26 weeks; iii) To assess self-reported reduction and cessation of other substance use at 13 and 26 weeks; and; iv) To describe the safety/tolerability of Cytisine or NRT SAEs, AEs, and drop-outs due to side effects, along with therapy adherence over 26 weeks; and, v) To compare lung function using oscillometry and spirometry, as well as self-efficacy at baseline, 13 weeks, and 26 weeks; Tertiary: i) To assess the cost-effectiveness of the pragmatic tobacco dependence strategies.
Study Design: A multi-centre pragmatic RCT trial comparing Cytisine (with nicotine) with counseling or NRT with counseling for a 13-week treatment period and 26-week follow up. Similar to the real world, all participants will be given an opportunity to choose either strategy at 26 wks. The primary analysis will be change in QOL and GAINSS score measured with the EQ-5D-5L at 13 weeks between participants.
Setting: 1) The Bridge Engagement Centre, Ottawa, adjacent to the largest homeless shelter downtown; and 2) The Parkdale Activity-Recreation Centre.
Expertise: The PI is well versed in community-based research and very experienced in tobacco dependence and the target population. She led the PROMPT project, a community-based smoking cessation project engaging the same target population.
Outcomes: Pragmatic community-based participatory and peer-led research holds a tremendous potential in investigating solutions 'for the people, by and with the people'. Outcomes of this trial will aid policy makers in implementing effective programs to treat tobacco dependence in marginalized population. The cost-effective community-based framework of this trial can be used as a template for intervention in other chronic diseases (e.g. obesity or diabetes).
Timeline: The trial will require 3 yrs to complete.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nicotine Replacement Therapy (NRT): nicotine mouth spray, nicotine patches, nicotine gum, nicotine lozenges, and nicotine oral inhalers
Drug: Nicotine replacement therapy (NRT)
Cytisine: 2x 1.5mg capsules 3 times a day (3mg 3 times a day).
Drug: Cytisine
Cytisine: 2x 1.5mg capsules 3 times a day (3mg 3 times a day).
Nicotine Replacement Therapy (NRT): nicotine mouth sprays, nicotine patches, nicotine gum, nicotine lozenges, and nicotine oral inhalers
Overall Quality of Life
To assess impact of two tobacco dependence strategies on quality of life (QOL) measured by questionnaire (EQ-5D-5L scores)
Time frame: 13 weeks
Smoking Prevalence
To assess effectiveness of two strategies (Cytisine with smoking cessation counseling vs NRT with smoking cessation counseling) with biochemically validated smoking abstinence at 13 and 26 weeks
Time frame: 26 weeks
Tobacco and e-cigarette (with nicotine) use
To assess effectiveness of these two strategies on conventional cigarette and/or e-cigarette consumption reduction and cessation at 13 and 26 weeks
Time frame: 26 weeks
Substance use
To assess self-reported reduction and cessation of other substance use at 13 and 26 weeks
Time frame: 26 weeks
Safety and tolerability of Cytisine or NRT
To describe the safety/tolerability of Cytisine or NRT SAEs, AEs, and drop-outs due to side effects, along with therapy adherence over 26 weeks
Time frame: 26 weeks
Lung function
To compare lung function using oscillometry and spirometry, as well as self-efficacy at baseline, 13 weeks, and 26 weeks
Time frame: 26 weeks
Cost-effectiveness
To assess the cost-effectiveness of the pragmatic tobacco dependence strategies
Time frame: 26 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Mar 2027, 16 months after the start.
Of 257 non-industry interventional studies with no phase under Tobacco Use Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 16 months is below that.
Counting every sponsor, half of 267 studies reached it within 32 months; a quarter within 16 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cytisine
Ottawa Hospital Research Institute →